Table 3. Associations between maternal 25(OH)D levels and allergic outcomes (odds ratio and 95% confidence intervals).

	25(OH)D sufficiency (≥ 75nmol/l) OR (95% CI)*	25(OH)D insufficiency (≥50 nmol/l and <75 nmol/l) OR (95% CI)*	25(OH)D deficiency (<50 nmol/l) OR (95% CI)*
Outcomes by month 18
Allergen sensitization	Ref	0.7 (0.3-1.3)	1.2 (0.5-2.6)
Eczema	Ref	0.9 (0.5-1.6)	1.4 (0.7-2.9)
Rhinitis	Ref	0.9 (0.5-1.6)	0.9 (0.4-2.1)
Wheeze and use nebulizer	Ref	0.7 (0.3-1.5)	0.7 (0.3-1.8)
Outcomes by month 36
Allergen sensitization	Ref	0.6 (0.3-1.1)	1.2 (0.6-2.5)
Eczema	Ref	1.0 (0.6-1.8)	1.5 (0.8-3.1)
Rhinitis	Ref	1.1 (0.7-2.0)	1.3 (0.6-2.8)
Wheeze and use nebulizer	Ref	0.6 (0.3-1.2)	0.5 (0.2-1.3)
Outcomes by month 60
Allergen sensitization	Ref	0.7 (0.4-1.1)	0.9 (0.4-1.8)
Eczema	Ref	1.1 (0.6-1.8)	1.6 (0.8-3.2)
Rhinitis	Ref	1.2 (0.7-2.1)	1.3 (0.6-2.7)
Wheeze and use nebulizer	Ref	1.0 (0.6-1.7)	0.9 (0.4-1.9)

^*Adjusted for sex, ethnicity, maternal education levels, maternal age, maternal BMI during pregnancy, family history of allergy, total energy intake during pregnancy and vitamin D supplementation.